Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 501–600 of 705
Farshbafnadi, M., Razi, S., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00008-6 · Cited by 2
Miranda, M. A., Macias-Velasco, J. F., Schmidt, H. K., & Lawson, H. A. (2023) · BMC Genomics · doi:10.1186/s12864-023-09232-5 · Cited by 2
“Currently, transplantation of cadaveric islets is the only method for restoring β-cell mass in diabetes but is severely limited by donor availability and requires lifelong immunosuppressant therapy [7, 8].”
MethodZhou, H., & Tullius, S. G. (2024) · Transplantation · doi:10.1097/tp.0000000000005086 · Cited by 2
Bal, T. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01919-y · Cited by 2
“However, donor shortage and source, and related issues such as disease transmission [32], requirement of multiple transplants [33] and risks of transplantation [34] limit widespread application of the islet transplantation in the clinics.”
Islet Xenotransplantation for the Treatment of Type 1 Diabetes
Shimoda, M., & Matsumoto, S. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1802008 · Cited by 2
Ling, Y., Gill, A., Oram, R. A., Shapiro, A. M. J., & Senior, P. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.039 · Cited by 2
Self-citationLong term (4 years) improved insulin sensitivity following islet cell transplant in type 1 diabetes
Rydzon, B., Monson, R. S., Oberholzer, J., Varady, K. A., Bellin, M. D., & Danielson, K. K. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2972 · Cited by 2
Self-citationLeal‐Lopes, C., Mantovani, M. D. C., & Sogayar, M. C. (2018) · Vigilância Sanitária em Debate · doi:10.22239/2317-269x.01056 · Cited by 2
Pancreas Retrieval for Whole Organ and Islet Cell Transplantation
Hawthorne, W. J., Hameed, A. M., & Pleass, H. C. C. (2018) · InTech eBooks · doi:10.5772/intechopen.75151 · Cited by 2
“This is largely because the entire reserve of islets remains intact in the whole organ graft rather than being removed, and a smaller proportion is transplanted in the cellular graft [66, 99].”
BackgroundBellin, M. D., Kim, T., Wilhelm, J. J., Schwarzenberg, S. J., & Chinnakotla, S. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15570 · Cited by 2
Self-citationLee, D., Gillard, P., Hilbrands, R., Ling, Z., de Velde, U. V., Jacobs‐Tulleneers‐Thevissen, D., Maleux, G. A., Lapauw, B., Crenier, L., Block, C. E. M. D., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003321 · Cited by 2
Current Assessment of Clinical Pancreatic Islet Allotransplantation
Chhabra, P., & Brayman, K. L. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2004125 · Cited by 2
Sakai‐Yonaha, M., Miyagi‐Shiohira, C., Kuwae, K., Tamaki, Y., Nishime, K., Yonaha, T., Saitoh, I., Watanabe, M., & Noguchi, H. (2021) · Transplantation · doi:10.1097/tp.0000000000003636 · Cited by 2
In vivo engraftment into the cornea endothelium using extracellular matrix shrink-wrapped cells
Palchesko, R. N., Du, Y., Geary, M. L., Carrasquilla, S. D., Shiwarski, D. J., Khandaker, I., Funderburgh, J. L., & Feinberg, A. W. (2022) · Communications Materials · doi:10.1038/s43246-022-00247-1 · Cited by 2
“As an alternative, cell-based therapies have long been thought of as a potential therapeutic option for a range of diseases and injuries caused by tissue and organ failure such as myocardial infarction 3 , diabetes 4,5 , corneal blindness 6 , and cystic fibrosis 7,8 .”
Skeletal Myoblast Cells Enhance the Function of Transplanted Islets in Diabetic Mice
Kado, T., Tomimaru, Y., Kobayashi, S., Harada, A., Sasaki, K., Iwagami, Y., Yamada, D., Noda, T., Takahashi, H., Kita, S., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5574968 · Cited by 2
“Most ITx recipients initially experience freedom from life-threatening hypoglycemic events; however, they commonly lose insulin independence by 3 years after ITx, due to early graft loss [5, 6].”
BackgroundRickels, M. R., Stock, P. G., de Koning, E. J. P., Piemonti, L., Pratschke, J., Alejandro, R., Bellin, M. D., Berney, T., Choudhary, P., Johnson, P. R., et al. (2018) · Data Archiving and Networked Services (DANS) · Cited by 2
Self-citationHarlan, D. M. (2017) · Diabetes Care · doi:10.2337/dci17-0013 · Cited by 2
Hering, B. J., Bridges, N. D., Eggerman, T. L., & Ricordi, C. (2017) · Diabetes Care · doi:10.2337/dc16-2691 · Cited by 2
Self-citationMicroscale Tissue Engineering and Contributors of the Cellular Niche
Al-Ani, A. (2019) · doi:10.11575/prism/36618 · Cited by 2
Hughes, K. S. (2020) · Deep Blue (University of Michigan) · Cited by 2
Insulin resistance-driven beta-cell adaptation in mice: Mechanistic characterization and 3D analysisPreprint
Liboz, A., Beaupère, C., Roblot, N., Tinévez, J.-Y., Guilmeau, S., Burnol, A., Gueddouri, D., Prieur, X., Fève, B., Guillemain, G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.09.523222 · Cited by 2
Kattner, N., Carlsson, P., & Scott, W. E. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100046 · Cited by 1
Brief Review: Pancreatic Islet Transplantation for Type 1 Diabetes in Humans
Robertson, R. P. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2302184 · Cited by 1
Pancreas Transplantation Alone for Brittle Diabetes Mellitus
Gruessner, R. W. G. (2023) · ES Journal of Case Reports · doi:10.59152/esjcr/1044 · Cited by 1
Raj, N., Karmakar, A., Narayan, G., & Thummer, R. P. (2025) · Advances in experimental medicine and biology · doi:10.1007/5584_2025_859 · Cited by 1
Exogenous vs Endogenous Insulin Delivery: 2025
Patel, A., Todd, R., Owen‐Simon, N. L., & McCune, K. R. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00468-6 · Cited by 1
“In 2023 the Food and Drug Administration (FDA) approved the first deceased donor islet product in the US, donislecal [73–75].”
InfluentialAdvances in Islet Function Replacing Strategies After Total Pancreatectomy
Peng, S., Zhao, B., Yi, X., Li, X., Zhang, J., Wang, J., & Li, R. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.012 · Cited by 1
Eilandjestransplantatie nu en in de toekomst
Hauck, R., de Vos, W., Engelse, M. A., Huurman, V. A. L., Nijhoff, M. F., & de Koning, E. J. P. (2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1598-7 · Cited by 1
Impact of circadian rhythm on differentiation and maturation of insulin-producing cells
Moon, J. E., Jeong, S., Shim, I. K., & Kim, S. C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152638 · Cited by 1
Direct Epigenetic Reprogramming of Human Somatic Cells into Insulin-Producing Cell
Naqvi, R. A., Naqvi, A. R., Priyadarshini, M., & Prasad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v13i9.6852 · Cited by 1
Benefit of Islet Transplantation in Type 1 Diabetes: A Systematic Review and Meta-Analysis
Wu, X.-Q., He, J., Wang, Z.-G., Qin, H., & Cao, J.-Z. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0041 · Cited by 1
Recent Advances in the Management of Type 1 Diabetes in Children
Beck, N. L. (2026) · Advances in Pediatrics · doi:10.1016/j.yapd.2025.12.012 · Cited by 1
Pancreatic tissue engineering: towards a vascularized bioengineered cure for diabetes
Park, J., Olawuyi, K., Jikaria, N. R., Dawes, J. S., Dabsha, I. E., Dick, A. A., & Ravnic, D. J. (2026) · Frontiers in Transplantation · doi:10.3389/frtra.2026.1768497 · Cited by 1
Guttikonda, S., Machur, J. C., Matha, C. P., Mathew, R. R., & Thotakura, T. (2026) · Cureus · doi:10.7759/cureus.111930 · Cited by 1
Larijani, M. R., Ashtiani, M. K., Tahamtani, Y., Alizadeh, S., Ghezelayagh, Z., Moradmand, A., Aghayan, H. R., & Larijani, B. A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02085-1 · Cited by 1
Current state of the problem of allotransplantation of Langerhans cells (achievements and prospects)
Alekberzade, A. V., Крылов, Н. Н., Adzhun, Z., Laftavi, M. R., Shakhbazov, R. O., & Zuykova, K. S. (2018) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia201811180 · Cited by 1
THE CURRENT STATE OF PANCREATIC ISLET TRANSPLANTATION
Anazawa, T., Okajima, H., & Üemoto, S. (2016) · Japanese Journal of Transfusion and Cell Therapy · doi:10.3925/jjtc.62.635 · Cited by 1
Pig-to-Nonhuman Primate (NHP) Naked Islet Xenotransplantation
Shin, J., Kim, J. M., Min, B., Kim, J.-S., Yoon, I., Chung, H., Lee, W., Kang, H. J., & Park, C. (2017) · InTech eBooks · doi:10.5772/intechopen.69001 · Cited by 1
“Hering et al. very recently published an important result from a Phase 3 clinical trial, which had intended to test the efficacy and safety of the standardized human pancreatic islet product in the patients with impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs).”
BackgroundInfluentialPancreas and Islet Allotransplantation
Witkowski, P., Solomina, J., & Millis, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-40232-3.00104-7 · Cited by 1
Islet Identity in Transplantation Procedures: The Intersection of Cellular Maturity and Function
Beamish, C. A., & Sabek, O. M. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1901055 · Cited by 1
“Islet transplantation is an effective and relatively noninvasive procedure for restoring endogenous insulin production and protecting against both severe hypoglycemia and microvascular complications [3-7], thus improving glycemic control and quality of life even in those grafts which retain only partial function [8, 9…”
BackgroundCellular therapies in preclinical and clinical islet transplantation: Mesenchymal stem cells
Korsgren, O., & Scholz, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00064-2 · Cited by 1
Self-citationProcedure-related and medical complications in and after intraportal islet transplantation
Lee, F. T., & Luo, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00046-0 · Cited by 1
Self-citationFilling the gap to improve islet engraftment and survival using anti-inflammatory approaches
Dugnani, E., & Citro, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00059-9 · Cited by 1
Islet isolation for autotransplantation, following total or near total pancreatectomy
Linetsky, E., & Ricordi, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00004-x · Cited by 1
Self-citationZhu, H., Zhang, X., He, Y., Yu, L., Lü, Y., Pan, K., Wang, B., & Chen, G. (2018) · Europe PMC (PubMed Central) · doi:10.7507/1002-1892.201707049 · Cited by 1
The Future of Clinical Islet Transplantation in the United States
Knoll, M. F., Knoll, C. A., Bottino, R., Bertera, S., & Trucco, M. (2021) · OBM Transplantation · doi:10.21926/obm.transplant.2101140 · Cited by 1
“CIT-07 demonstrated that (i) optimized islet manufacturing methods and protocols can be established and carried out in multiple centers [54] and that; (ii), allogeneic islet Tx was safe and effective treatment for patients with labile T1D [19] that improved quality of life for patients [11].”
BackgroundMethodInfluentialBalamurugan, A. N., Samaga, K. K., Narayanan, S., Kodipad, A. A., Mokshagundam, S. P., & Nathan, J. D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824011-3.00008-4 · Cited by 1
Kelly, A. C., Suszynski, T. M., & Papas, K. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824011-3.00010-2 · Cited by 1
Kim, J. M., Bottino, R., & Park, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824011-3.00005-9 · Cited by 1
Lablanche, S., Camille, L., & Benhamou, P. (2019) · Springer eBooks · doi:10.1007/978-3-319-98119-2_7 · Cited by 1
Xing, Y., Li, L., Yu, X., Fox, E. G., Wang, Y., & Oberholzer, J. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00377-y · Cited by 1
Self-citationKnatterud, M. E., Simmons, R. L., Payne, W. D., Stock, P. G., Chavers, B. M., Ascher, N. L., Kaufman, D. B., Kirk, A. D., Keshavjee, S. H., Humar, A., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14877 · Cited by 1
Self-citationCheah, Y. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.364 · Cited by 1
Ogledzinski, M., Bachul, P. J., Rezania, K., Hariprasad, S. M., Gondek, S., Lin, W., Juengel, B., Milejczyk, K., Basto, L., Wang, L., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.14981 · Cited by 1
Ponomareva, A. S., Baranova, N. V., Nikolskaya, A. O., Кирсанова, Л. А., Онищенко, Н. А., Гоникова, З. З., Bubentsova, G. N., Volkova, E. A., Basok, Y. B., & Sevastianov, V. I. (2023) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2023-2-107-117 · Cited by 1
Transplantation of Pancreatic Islets
Rao, J. S., Bellin, M. D., & Hering, B. J. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch166 · Cited by 1
Self-citationDefining Outcomes for β-Cell Replacement Therapy
Rickels, M. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_65 · Cited by 1
Self-citationPancreas Transplantation Alone
Gruessner, R. W. G., & Gruessner, A. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_24 · Cited by 1
Berney, T., Andrès, A., Wassmer, C., & Berishvili, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_84 · Cited by 1
Whole Pancreas and Islet Cell Transplantation
Marfil‐Garza, B. A., Senior, P. A., & Shapiro, A. M. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch34 · Cited by 1
Self-citationAn Ethical Perspective on the Social Value of Cell-Based Technologies in Type 1 Diabetes
de Jongh, D., & Bunnik, E. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_19 · Cited by 1
Rickels, M. R., Bellin, M. D., Stefanovski, D., Peleckis, A. J., DALTON-BAKES, C. V., Markmann, E., Nguyen, H.-L., Townsend, R. R., Hering, B. J., & Naji, A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00002.2024 · Cited by 1
Self-citationPancreatic Islet Microphysiology System for Disease Modeling of Type 2 Diabetes
Wiegand, C. (2024) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Transplantation of Pancreatic Islets
Hering, B. J., & Bellin, M. D. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch147 · Cited by 1
Self-citationImproving islet-graft revascularization
Figueiredo, A., & Hugo, J. (2018) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Islet Autotransplantations for Total Pancreatectomy
Sakata, N., Yoshimatsu, G., & Kodama, S. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1902059 · Cited by 1
Pancreatic Islet Transplantation: State of the Art and Future Perspectives
Donatini, G., Giraud, S., Kraimps, J., Danion, J., & Hauet, T. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1902062 · Cited by 1
Youngblood, R. L. (2020) · Deep Blue (University of Michigan) · Cited by 1
Editorial: Xenotransplantation for the therapy of diabetes: A new look
Yamada, K., & Bottino, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1190442 · Cited by 1
“Even if recent advances, including more efficacious immunosuppressive protocols, have improved the outcome of islet Tx (5), the availability of allogeneic islets remains one of the major obstacles to the progress of allogeneic islet transplantation; this is made worse by the fact that as many as 50% of the cases repor…”
BackgroundLiboz, A. (2022) · theses.fr (ABES) · doi:10.70675/9abd3277zd4c4z48f5za637z73aeb8a7a807 · Cited by 1
Autologous stem-cell derived islets — the ultimate frontier in diabetes mellitus?
Shapiro, A. M. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01064-x · Cited by 1
Self-citationCan Islet Transplantation Possibly Reduce Mortality in Type 1 Diabetes
Isenberg, J. S., & KANDEEL, F. R. (2025) · Cell Transplantation · doi:10.1177/09636897241312801 · Cited by 1
Status Post Total Pancreatectomy
Kotsifa, E., & Mavroeidis, V. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-40858-8_470-1 · Cited by 1
Yetişkin diyabet bilgi ölçeği’nin (ydbö) geliştirilmesi
Yavuz, K. E. (2019) · Dspace Repository (Marmara Üniversitesi) · Cited by 1
Development of an in vitro screening platform for research of Type 1 Diabetes therapies
Porter, J. (2024) · eScholarship@McGill (McGill) · doi:10.82308/18764 · Cited by 1
Exploring immune cell functions and ways to make use of them
Vågesjö, E. (2016) · Uppsala University Publications (Uppsala University)
Islet/stem cell transplantation – what's new?
Spiliotis, I., & Johnson, P. (2017) · Paediatrics and Child Health · doi:10.1016/j.paed.2017.01.004
Targeting Fas pathway as an effective means of inducing tolerance to pancreatic islets.
Woodward, K. B. (2017) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2759
Caminhando para cura da Diabetes Mellitus Tipo 1
Marques, M. S. D. S. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/2371-1h28
New insights into autoimmune mediated neonatal diabetes
Johnson, M. B. (2017) · Figshare
Coutant, R., Tubiana‐Rufi, N., Leroy, C., Lefebvre, C., Gueorguieva, I., Cartigny, M., Lablanche, S., & Benhamou, P. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00012-4
Stefenon, P. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Lyu, J. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/2jra-yr02
Shimoda, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88324
Role of the Interventional Radiologist in Pancreatic Whole Organ and Islet Cell Transplantation
Shah, K. Y., Simpson, R. O., Wang, Y., Okoye, O. T., Pandhi, M. B., Desai, S. S., & Alvarez, J. A. A. (2019) · Digestive Disease Interventions · doi:10.1055/s-0039-1700508
UK’s nationally funded integrated islet transplant program
Flatt, A. J., Counter, C., Johnson, P., & Shaw, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00049-6
Asthana, A., Muir, S. M., Chaimov, D., & Orlando, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00025-7
Latres, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00036-1
Investigating Ectopic Sites for Islet Transplantation
Salama, B. F. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-md1t-t023
Treating diabetes with islet transplantation: Lessons from the University of Miami
Camhi, S. S., Baidal, D. A., Alejandro, R., Alvarez, A., Padilla, N., Linetsky, E., Kenyon, N. S., & Ricordi, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00053-8
Self-citationSpiers, R. M. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-konr68ajj
Carnosine, pancreatic protection, and oxidative stress in type 1 diabetes
Miceli, V., & Conaldi, P. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815776-3.00020-6
Islet Transplantation in Type 1 Diabetes Mellitus With Hypoglycaemic Unawareness
Agarwal, G., & Cross, S. (2020) · Journal of the Nuffield Department of Surgical Sciences · doi:10.37707/jnds.v1i4.74
Novel approaches to pancreas allograft surveillance
Barnes, J. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-go8r6v9oo
Xenotransplantation literature update, July/August 2020
Nanno, Y., & Burlak, C. (2020) · Xenotransplantation · doi:10.1111/xen.12653
Pancreas vs. Islet Transplantation: the False Dilemma
Wijkstrom, M. N. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00299-7
Pancreas preservation with amphotericin B deteriorates islet yield for porcine islet isolation
Sawada, S., Miyagi‐Shiohira, C., Kuwae, K., Tamaki, Y., Nishime, K., Sakai‐Yonaha, M., Yonaha, T., Saitoh, I., Watanabe, M., & Noguchi, H. (2021) · Xenotransplantation · doi:10.1111/xen.12690
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.